After Cuba, Japan: Hope, Marketing and Evidence in Cancer Treatment Packages

Hope Sold Under a “Japanese Quality” Label: We Reviewed a One-Month Pancreatic Cancer Package Item by Item

A few years ago, cancer patients from Turkey were traveling to Cuba in the hope of a "lung cancer vaccine"; we have previously examined the reality of cancer in Cuba through Cuba's own official data. Today, a similar trend is growing toward Japan. Japan's standard oncology is among the best in the world, yet the same country also hosts a second market of treatments that are unproven and paid entirely out of the patient's pocket. Drawing on our own evidence report, this article examines the claims, the views of Japanese experts and a real pancreatic cancer package offered to a Turkish patient, point by point.

Why does this matter?

The narrative of "a cure hidden in another country" is not new in oncology. Cuba's CIMAvax vaccine, reports that Russia had "found the cancer vaccine" and the long-running clinics in Mexico and Germany have followed a similar pattern: a genuine scientific advance, or a country's prestige, is carried over into the marketing of products with weak evidence. This trend tends to concentrate on the most difficult diseases, and pancreatic cancer is near the top of that list, even though real, evidence-based advances are also taking place in this field.

The Japanese case is more complex than the Cuban one. In Cuba, the product was weak but singular. In the Japanese packages, one or two components with strong evidence lend credibility to many components with weak evidence. This makes it difficult for patients and families, and even for physicians, to evaluate the package. There are no published data on the number of Turkish patients traveling to Japan; demand is growing through intermediary companies and Turkish-language marketing pages before any public debate has taken place.

Is it worth going to Japan for cancer treatment?

For most patients, no. The evidence-based contribution unique to Japan is limited: for example, carbon ion therapy in some selected patients without metastases. The efficacy of the cell therapies, vaccines, hydrogen and plasma sessions in these packages is unproven. Most new drugs are also available in Turkey or can be obtained through the named-patient import route via the Turkish Pharmacists' Association (TEB). An independent multidisciplinary tumor board opinion should be obtained before making a decision.

Cuba and Japan: the same story in new packaging

The lesson from Cuba is clear: even the best Phase 3 data for the Cuban vaccines showed an uncertain benefit measured in months, yet demand was fed by narrative, not evidence. In Japan, the same narrative is reinforced with the assurance of "Japanese technology" and a "legal framework." On Turkish-language marketing pages, NK cell therapy is advertised at approximately ¥660,000 (about $4,400) for a single session, and comprehensive packages at prices above ¥7.5 million ($50,000).

Why Japan? Five factors driving demand

Japan's appeal rests largely on real achievements. The problem is that these achievements are carried over into the marketing of free-pay clinics.

1. Genuine scientific prestige: Tasuku Honjo's 2018 Nobel Prize in Physiology or Medicine for the discovery of PD-1, the world's first approval of photoimmunotherapy in Japan (2020) and its carbon ion centers. These are real; but they are often not what the clinics are selling.
2. The perception of "legality": The 2014 regenerative medicine law (ASRM) allows cell therapy to be offered on a free-pay basis after committee review and plan notification to the ministry, without going through the drug approval process. The law does not distinguish between innovation and unproven practice.
3. Regional patient flows: Korean medical circles estimate that 10,000–20,000 Korean cancer patients travel to Japan each year; Korea amended its law in 2024 (effective 2025) to bring these patients back. In 2020, the Japanese government estimated the number of Chinese patients coming for advanced cancer treatment at approximately 1,000.
4. The intermediary ecosystem: Because of the language barrier, patients depend on packages. One intermediary working with Chinese patients explains that cancer treatment costs approximately ¥10 million, with the brokerage fee added on top.
5. Desperation and the "last chance" narrative: The anxiety and hopelessness that come with a serious diagnosis make decision-making harder. In Japan, approximately 40% of patients use a complementary or alternative method; these methods can delay standard treatment and worsen survival.

What does "legal" mean in Japan? Three separate levels

Common claims and the reality

We compared the main claims circulating on intermediary pages and in patient groups with primary sources.

The sharpest criticism comes from Japan's own oncologists

A survey by researchers at Japan's National Cancer Center (NCC), announced in early 2026, and a 2025 study of members of the Japanese Society of Medical Oncology (JSMO) put numbers to how specialists view uninsured treatments. The practices specialists are asked about most often are NK and NKT cell, dendritic cell and exosome therapies. In open-ended responses, words such as "deceptive" and "exploitative," along with debt and the financial ruin of families, stand out.

The researchers also highlight an important communication problem: most oncologists remain neutral in consultations out of respect for patient autonomy, but patients may perceive this neutrality as approval. This is a lesson for Turkey as well. Saying "it's your decision" is no substitute for saying "there is no evidence for this."

• Professional societies: In 2019, the Japan Society of Clinical Oncology warned the public about free-pay cell and vaccine therapies and recommended seeking a second opinion first. The national federation of cancer patient groups issued a similar warning in 2018.
• Investigative journalism: Toyo Keizai reported that none of the immunotherapies offered at more than 300 private clinics had been proven in clinical trials. A Japanese oncologist working at MD Anderson pointed out that, elsewhere in the world, unproven treatments are tested free of charge to patients within clinical trials.
• International literature: Analyses in Cell Stem Cell describe the Japanese model as "broad permission, regulation afterward."

The international view can be summarized as follows: Japan's standard oncology is world-class; the problem is that the "Japanese quality" label is carried over to the same country's second, uninsured market.

Why are patients complaining?

Six patterns recur in the Japanese press, in patient groups and in physician surveys. For Turkish patients, the risk is even greater because of language and distance.

1. Unclear and escalating costs: One patient reportedly paid approximately ¥2.5 million for a course of NK cell therapy, and hydrogen sessions are said to start at ¥20,000 per session and grow with additional prescriptions.
2. Delay of standard treatment: Turning to free-pay treatment can delay the start of standard treatment and worsen survival. In pancreatic cancer, even a few weeks can change a patient's general condition and eligibility for treatment.
3. The mixed-billing trap: In Japan, combining insured treatment with free-pay treatment can result in the standard portion also being billed entirely to the patient. Foreign patients have no insurance in any case, but the same logic recurs with "in-package" and "out-of-package" items.
4. A care gap after returning home: 91.3% of specialists consider post-clinic care inadequate. For a Turkish patient, this may mean returning to their care team in Turkey with a possible complication but without records, images or a discharge summary.
5. Misleading presentation of success: "The cancer disappeared" advertisements, allegations that the imaging method was changed to make a tumor appear to have vanished, and uncontrolled "clinical improvement rates." Data that look sound on the surface are the main tool of this market.
6. Diffused responsibility: A university hospital, several private clinics, a heavy ion center and an intermediary company: who is responsible for which complication? Package documents often exclude liability with a statement that they "are not an informed consent document."

Approximate cost of a free-pay cancer treatment course

Dollar equivalents are approximate and intended only to give a sense of scale; they do not include travel, accommodation, a companion or interpreting. For comparison, see the current oncology drug prices in Turkey.

A sample offer: "1-month multidisciplinary program in Japan" for pancreatic cancer

We reviewed an 18-page offer that an intermediary company presented to a Turkish patient, with the patient's identity removed. The offer itself candidly acknowledges some limits of the evidence, which makes it more persuasive than typical brochures. We classified the components into four groups by level of evidence: A Phase 3 trial or licensed indication; B selected patient series, non-randomized data; C laboratory-level data, case reports or company data; D no antitumor evidence.

The offer also presents Nagasaki University Hospital as a "core" genomic medicine hospital. On the Japanese Ministry of Health list, Nagasaki is not one of the roughly 13 core centers but one of 32 "designated cancer genomic medicine hospitals." A small but typical exaggeration of status.

The structural problem: this is not a treatment plan but a menu

More important than the evidence for each component is how they are put together. Two structural problems stand out.

Problem 1: indications that cannot apply to the same patient at the same time

In pancreatic cancer, treatment is determined first and foremost by stage. In resectable or borderline resectable disease, surgery and chemotherapy; in non-metastatic locally advanced disease, chemotherapy and radiotherapy in selected patients; and in metastatic disease, systemic therapy takes the lead. The offer counts the treatments for all three groups as "included in the package" at the same time.

Problem 2: a schedule that does not fit into one month

As a result, the response becomes uninterpretable, side effects overlap and the schedule remains internally inconsistent.

Red flags in the offer

• Blank budget fields: Sentences such as "a budget of up to … for the targeted drug" contain no amount; the total price does not appear anywhere in the document.
• A template program: Treatments belonging to mutually exclusive stages are included in the same package.
• Halo effect: Two strong items (daraxonrasib and, in selected patients, carbon ion therapy) lend credibility to the weak ones.
• Off-label and laboratory-level practices are included in the package price; consent is to be obtained "separately if needed."
• Exaggerated status: Verifiable but incorrect statements such as "core center."
• Disclaimer of liability: The document describes itself as "not an informed consent document or a guarantee of outcome."

To be fair, the numerical data in the offer (RASolute 302, NAPOLI-1, J-CROS) are cited correctly, the limits of the evidence are stated plainly in many sections, no outcome is guaranteed, and surgery and CAR-T manufacturing are explicitly excluded from the package. But this makes the document more persuasive, not more reliable. Warnings that appear honest do not prevent the purchase of the unproven items in the same package.

10 questions patients and physicians should ask the intermediary company

1. What is the patient's current stage, and which items in the package apply to that stage? Are the items that do not apply deducted from the price?
2. What is the total price, and what is the price of each item? What are the amounts in the blank budget fields?
3. Which agent and which light device will be used for photoimmunotherapy? Is this agent approved in Japan for pancreatic cancer?
4. If no suitable artery is found, will the catheter fee be refunded?
5. Will the carbon ion center accept the patient before departure, or will acceptance only be determined in Japan?
6. How will daraxonrasib be legally obtained in Japan? Could it be obtained in Turkey through the TEB named-patient import route?
7. What exactly are the plasma-hydrogen and "immune booster" treatments in the package: a product or a device, and what are their licensing status and dose?
8. If a complication occurs, who is responsible, which hospital will the patient be admitted to, and who will pay the costs?
9. On return, will the oncologist in Turkey receive a complete discharge summary, images and pathology reports in English?
10. Does the intermediary company disclose whether it receives commissions from Japanese clinics?

Frequently asked questions

Is cancer treatment in Japan better than in Turkey?

Japan is world-class in standard cancer treatment, but most guideline-based treatments are also available at experienced centers in Turkey. The evidence-based contribution unique to Japan is limited, and the efficacy of the cell and vaccine therapies offered by free-pay clinics is unproven.

Does NK cell therapy in Japan work for cancer?

There is no controlled study showing that free-pay NK cell therapy prolongs survival in cancer patients. 94.9% of Japanese cancer specialists reject the efficacy of such uninsured treatments. A single session costs around $4,400.

Is a treatment that is legal in Japan effective?

Not necessarily. Japan's 2014 regenerative medicine law regulates the safety and procedures of cell therapies, not their efficacy. Licensed drug approval and permission to offer a free-pay treatment are two different things.

Who is a candidate for carbon ion therapy in pancreatic cancer?

Carbon ion therapy has been studied in selected patients with non-metastatic, locally advanced pancreatic cancer; in the Japanese series, 2-year survival was 46%, but the data are not randomized. It has no indication in metastatic pancreatic cancer.

Glossary

Free-pay treatment (jiyū shinryō)

Medical care in Japan that falls outside national health insurance coverage and is paid entirely out of the patient's pocket.

Act on the Safety of Regenerative Medicine (ASRM)

Japanese law that took effect in 2014, regulating the safety and procedures of cell therapies without requiring evidence of efficacy.

Photoimmunotherapy

A method that targets cancer cells by activating a tumor-binding antibody-dye conjugate with a specific light; approved in Japan only for head and neck cancer.

Photodynamic therapy

A method, distinct from photoimmunotherapy, in which a light-sensitive agent is activated by light to cause tissue damage.

Carbon ion radiotherapy

A particle therapy using carbon nuclei that can deliver a high dose to the tumor while sparing surrounding tissue.

Halo effect

The positive perception of one strong element spilling over to weaker elements in the same package.